675 related articles for article (PubMed ID: 21417952)
1. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
4. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
6. PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.
Cook D; Meade M; Guyatt G; Walter SD; Heels-Ansdell D; Geerts W; Warkentin TE; Cooper DJ; Zytaruk N; Vallance S; Berwanger O; Rocha M; Qushmaq I; Crowther M
J Crit Care; 2011 Apr; 26(2):223.e1-9. PubMed ID: 21482348
[TBL] [Abstract][Full Text] [Related]
7. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L;
Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708
[TBL] [Abstract][Full Text] [Related]
8. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Cook D; Douketis J; Meade M; Guyatt G; Zytaruk N; Granton J; Skrobik Y; Albert M; Fowler R; Hebert P; Pagliarello G; Friedrich J; Freitag A; Karachi T; Rabbat C; Heels-Ansdell D; Geerts W; Crowther M;
Crit Care; 2008; 12(2):R32. PubMed ID: 18315876
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
11. Idraparinux versus standard therapy for venous thromboembolic disease.
; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
[TBL] [Abstract][Full Text] [Related]
12. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
13. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
[TBL] [Abstract][Full Text] [Related]
16. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
17. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
18. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
20. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
